Amicus Therapeutics(FOLD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FOLD Amicus Therapeutics

Trading 12-11 15:55:30 EST

9.87

+0.02

+0.15%

High9.96	Low9.74	Vol1.73M
Open9.86	D1 Closing9.85	Amplitude2.23%
Mkt Cap3.04B	Tradable Cap2.84B	Total Shares308.53M
T/O17.11M	T/O Rate0.60%	Tradable Shares288.21M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"FOLD","market":"US","secType":"STK","nameCN":"Amicus Therapeutics","latestPrice":9.865,"timestamp":1765486529649,"preClose":9.85,"halted":0,"volume":1733317,"delay":0,"floatShares":288206958,"shares":308533548,"eps":-0.045705,"marketStatus":"Trading","change":0.015,"latestTime":"12-11 15:55:30 EST","open":9.855,"high":9.96,"low":9.74,"amount":17105422.546102,"amplitude":0.022335,"askPrice":9.87,"askSize":6983,"bidPrice":9.86,"bidSize":6931,"shortable":3,"etf":0,"ttmEps":-0.045705,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1765486800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1180584000000,"exchange":"NASDAQ","adjPreClose":9.85,"preHourTrading":{"tag":"盘前","latestPrice":9.81,"preClose":9.85,"latestTime":"09:25 EST","volume":1482,"amount":14560.380276,"timestamp":1765463100049},"postHourTrading":{"tag":"盘后","latestPrice":9.72,"preClose":9.85,"latestTime":"19:33 EST","volume":1165012,"amount":11475282.505,"timestamp":1765413235087},"volumeRatio":0.493497,"impliedVol":0.7451,"impliedVolPercentile":0.824},"requestUrl":"/m/hq/s/FOLD","defaultTab":"news","newsList":[{"id":"2588007686","title":"Amicus Therapeutics CEO Bradley L. Campbell Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588007686","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588007686?lang=en_us&edition=fundamental","pubTime":"2025-12-04 09:12","pubTimestamp":1764810725,"startTime":"0","endTime":"0","summary":"Bradley L. Campbell, President and CEO of Amicus Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amicus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 03, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL4lBwFF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Amicus Therapeutics CEO Bradley L. Campbell Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FOLD","LU2065170008.USD","LU2065169927.USD","LU2065171311.SGD","LU2065171402.SGD","BK4139"],"gpt_icon":0},{"id":"2586329779","title":"Amicus Therapeutics Chief People Officer David Michael Clark Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586329779","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586329779?lang=en_us&edition=fundamental","pubTime":"2025-11-27 10:18","pubTimestamp":1764209906,"startTime":"0","endTime":"0","summary":"David Michael Clark, Chief People Officer of Amicus Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amicus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 26, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251127:nNDL1JClPy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","LU2065171402.SGD","BK4139","FOLD","LU2065170008.USD","LU2065171311.SGD"],"gpt_icon":0},{"id":"2586297760","title":"Amicus Therapeutics CEO Bradley L. Campbell Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586297760","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586297760?lang=en_us&edition=fundamental","pubTime":"2025-11-27 10:17","pubTimestamp":1764209873,"startTime":"0","endTime":"0","summary":"Bradley L. Campbell, President and CEO of Amicus Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amicus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 26, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251127:nNDL2KWtcy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Amicus Therapeutics CEO Bradley L. Campbell Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","BK4139","FOLD","LU2065170008.USD","LU2065169927.USD","LU2065171311.SGD"],"gpt_icon":0},{"id":"2585168469","title":"A Look at Amicus Therapeutics (FOLD) Valuation as GAAP Profitability and Sales Growth Reshape the Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2585168469","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585168469?lang=en_us&edition=fundamental","pubTime":"2025-11-21 04:26","pubTimestamp":1763670366,"startTime":"0","endTime":"0","summary":"Amicus Therapeutics (FOLD) has crossed an important threshold in Q3 2025 by reaching GAAP profitability, propelled by growing sales of its rare disease treatments Galafold and Pombiliti + Opfolda. This shift adds new context for investors.\nSee our latest analysis for Amicus Therapeutics.\nAfter a challenging few years, Amicus Therapeutics’ recent GAAP profitability has been accompanied by a clear upswing in the stock’s momentum, with a 15.3% share price return over the past month and a notable...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fold/amicus-therapeutics/news/a-look-at-amicus-therapeutics-fold-valuation-as-gaap-profita","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fold/amicus-therapeutics/news/a-look-at-amicus-therapeutics-fold-valuation-as-gaap-profita","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["FOLD"],"gpt_icon":0},{"id":"2581048098","title":"Amicus Therapeutics Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2581048098","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581048098?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:27","pubTimestamp":1762464420,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FOLD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 06, 2025 16:27 ET (21:27 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FOLD"],"gpt_icon":0},{"id":"2581597061","title":"Bank of America Securities Sticks to Its Buy Rating for Amicus (FOLD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581597061","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581597061?lang=en_us&edition=fundamental","pubTime":"2025-11-06 19:38","pubTimestamp":1762429084,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Tazeen Ahmad from Bank of America Securities reiterated a Buy rating on Amicus, with a price target of $14.00. The ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-sticks-to-its-buy-rating-for-amicus-fold-blurbs-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/bank-of-america-securities-sticks-to-its-buy-rating-for-amicus-fold-blurbs-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAC","FOLD"],"gpt_icon":0},{"id":"2581701640","title":"Amicus Therapeutics Chief People Officer David Michael Clark Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2581701640","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581701640?lang=en_us&edition=fundamental","pubTime":"2025-11-06 05:07","pubTimestamp":1762376845,"startTime":"0","endTime":"0","summary":"David Michael Clark, Chief People Officer of Amicus Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amicus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 05, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDLpS9qp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Amicus Therapeutics Chief People Officer David Michael Clark Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FOLD","LU2065170008.USD","LU2065169927.USD","LU2065171311.SGD","LU2065171402.SGD","BK4139"],"gpt_icon":0},{"id":"2581577731","title":"Amicus Therapeutics Is Maintained at Neutral by Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2581577731","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581577731?lang=en_us&edition=fundamental","pubTime":"2025-11-06 01:00","pubTimestamp":1762362000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FOLD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 05, 2025 12:00 ET (17:00 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FOLD"],"gpt_icon":0},{"id":"2581277468","title":"Cantor Fitzgerald Sticks to Its Buy Rating for Amicus (FOLD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581277468","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581277468?lang=en_us&edition=fundamental","pubTime":"2025-11-05 23:46","pubTimestamp":1762357593,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Amicus, with a price target of $21.00. Kluska cove...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-its-buy-rating-for-amicus-fold-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-its-buy-rating-for-amicus-fold-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FOLD"],"gpt_icon":0},{"id":"2581972775","title":"Morgan Stanley Sticks to Their Buy Rating for Amicus (FOLD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581972775","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581972775?lang=en_us&edition=fundamental","pubTime":"2025-11-05 22:15","pubTimestamp":1762352158,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Maxwell Skor from Morgan Stanley maintained a Buy rating on Amicus, with a price target of $12.00. The company’s sh...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-their-buy-rating-for-amicus-fold-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/morgan-stanley-sticks-to-their-buy-rating-for-amicus-fold-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FOLD"],"gpt_icon":0},{"id":"2581075212","title":"Amicus Therapeutics: Strong Q3 Performance and Strategic Advancements Justify Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2581075212","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581075212?lang=en_us&edition=fundamental","pubTime":"2025-11-05 01:25","pubTimestamp":1762277111,"startTime":"0","endTime":"0","summary":"Amicus, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Gil Blum from Needham maintained a Buy rating on the s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/amicus-therapeutics-strong-q3-performance-and-strategic-advancements-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/amicus-therapeutics-strong-q3-performance-and-strategic-advancements-justify-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FOLD"],"gpt_icon":0},{"id":"1109503348","title":"Stock Track | Amicus Therapeutics Soars 5.53% Pre-Market on Strong Q3 Results and Positive Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=1109503348","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109503348?lang=en_us&edition=fundamental","pubTime":"2025-11-04 23:10","pubTimestamp":1762269005,"startTime":"0","endTime":"0","summary":"Amicus Therapeutics (FOLD) shares are soaring 5.53% in pre-market trading on Tuesday following the release of its impressive third-quarter 2025 financial results. The biotechnology company, focused...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["FOLD"],"gpt_icon":0},{"id":"2580735862","title":"BRIEF-Amicus Therapeutics Q3 Revenue USD 169 Million Vs. IBES Estimate USD 165.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2580735862","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580735862?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:00","pubTimestamp":1762257654,"startTime":"0","endTime":"0","summary":"BRIEF-Amicus Therapeutics Q3 Revenue USD 169 Million Vs. IBES Estimate USD 165.2 Million\n\n\nNov 04 (Reuters) - Amicus Therapeutics Q3 net income USD 17 million.\n\nQ3 EPS USD 0.06\nQ3 adjusted operating expenses USD 95.4 million\nQ3 operating expenses USD 115.3 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nPLXB46E07:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","LU2065170008.USD","BK4139","LU2065171311.SGD","FOLD","LU2065169927.USD"],"gpt_icon":0},{"id":"2580735855","title":"Amicus Therapeutics Reports Q3 Revenue of $169 Million and Net Income of $17 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2580735855","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580735855?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:00","pubTimestamp":1762257641,"startTime":"0","endTime":"0","summary":"Amicus Therapeutics Inc. reported total revenues of $169.1 million for the third quarter of 2025, representing a 17.0% increase at constant exchange rates compared to the same period in the previous year. The company achieved a positive GAAP net income of $17.0 million for the quarter. Amicus ended the quarter with a cash position of $264.0 million, an increase of $33.0 million from the previous quarter. Business developments during the period included increased patient numbers, driven by new Galafold starts and growing adoption of Pombiliti + Opfolda, as well as continued enrollment progress in the Phase 3 study of DMX-200.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amicus Therapeutics Inc. published the original content used to g","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nNDL9tgcsx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2065170008.USD","LU2065171311.SGD","LU2210150020.SGD","BK4112","LU2095319765.USD","IE00B3QW5Z07.USD","LU0314104364.USD","LU2065169927.USD","IE00BGHQF748.EUR","BK4585","IE00B64PRP62.GBP","LU2065171402.SGD","LU2210149790.SGD","NDAQ","FOLD","BK4588","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2580735057","title":"Amicus Therapeutics Outlook FY Revenue Growth 15-22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580735057","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580735057?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:00","pubTimestamp":1762257609,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nPLXB46E07:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065169927.USD","FOLD","LU2065170008.USD","LU2065171402.SGD","BK4139","LU2065171311.SGD"],"gpt_icon":0},{"id":"2580735054","title":"Amicus Therapeutics Outlook FY Adjusted Operating Expenses USD 380-400 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2580735054","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580735054?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:00","pubTimestamp":1762257609,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nPLXB46E07:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU2065170008.USD","LU2065171311.SGD","LU2065169927.USD","LU2065171402.SGD","FOLD"],"gpt_icon":0},{"id":"2580735033","title":"Amicus Therapeutics Q3 Adjusted EPS USD 0.17 VS. Ibes Estimate USD 0.04","url":"https://stock-news.laohu8.com/highlight/detail?id=2580735033","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580735033?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:00","pubTimestamp":1762257609,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nPLXB46E07:8","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FOLD","BK4139","LU2065171402.SGD","LU2065169927.USD","LU2065171311.SGD","LU2065170008.USD"],"gpt_icon":0},{"id":"2580350257","title":"Amicus Therapeutics Inc: Anticipates Surpassing $1 Bln in Total Sales in 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2580350257","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580350257?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:00","pubTimestamp":1762257609,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nPLXB46E07:9","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065169927.USD","LU2065171402.SGD","BK4139","LU2065171311.SGD","LU2065170008.USD","FOLD"],"gpt_icon":0},{"id":"2580331107","title":"Amicus Therapeutics Q3 EPS USD 0.06","url":"https://stock-news.laohu8.com/highlight/detail?id=2580331107","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580331107?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:00","pubTimestamp":1762257609,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nPLXB46E07:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2065171311.SGD","FOLD","LU2065169927.USD","BK4139","LU2065170008.USD","LU2065171402.SGD"],"gpt_icon":0},{"id":"2579046874","title":"Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2579046874","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579046874?lang=en_us&edition=fundamental","pubTime":"2025-10-31 19:00","pubTimestamp":1761908400,"startTime":"0","endTime":"0","summary":"PRINCETON, N.J., Oct.  31, 2025  (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/31/3178217/15991/en/Amicus-Therapeutics-to-Present-at-Upcoming-Investor-Conferences-in-November-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2065169927.USD","LU2065171402.SGD","BK4588","FOLD","BK4581","LU2065171311.SGD","BK4139","XBI","LU2065170008.USD","LABU","XLV"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amicusrx.com","stockEarnings":[{"period":"1week","weight":0.0072},{"period":"1month","weight":0.0944},{"period":"3month","weight":0.2282},{"period":"6month","weight":0.6335},{"period":"1year","weight":-0.0276},{"period":"ytd","weight":0.0456}],"compareEarnings":[{"period":"1week","weight":0.0054},{"period":"1month","weight":0.009},{"period":"3month","weight":0.0455},{"period":"6month","weight":0.1517},{"period":"1year","weight":0.1406},{"period":"ytd","weight":0.1732}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.064574},{"month":2,"riseRate":0.5,"avgChangeRate":-0.04086},{"month":3,"riseRate":0.555556,"avgChangeRate":0.039527},{"month":4,"riseRate":0.388889,"avgChangeRate":-0.017744},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.009978},{"month":6,"riseRate":0.631579,"avgChangeRate":0.068706},{"month":7,"riseRate":0.578947,"avgChangeRate":0.084684},{"month":8,"riseRate":0.473684,"avgChangeRate":0.040961},{"month":9,"riseRate":0.368421,"avgChangeRate":-0.011223},{"month":10,"riseRate":0.315789,"avgChangeRate":-0.067456},{"month":11,"riseRate":0.578947,"avgChangeRate":0.061605},{"month":12,"riseRate":0.473684,"avgChangeRate":-0.027433}],"exchange":"NASDAQ","name":"Amicus Therapeutics","nameEN":"Amicus Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Amicus Therapeutics(FOLD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Amicus Therapeutics(FOLD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Amicus Therapeutics,FOLD,Amicus Therapeutics股票,Amicus Therapeutics股票老虎,Amicus Therapeutics股票老虎国际,Amicus Therapeutics行情,Amicus Therapeutics股票行情,Amicus Therapeutics股价,Amicus Therapeutics股市,Amicus Therapeutics股票价格,Amicus Therapeutics股票交易,Amicus Therapeutics股票购买,Amicus Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Amicus Therapeutics(FOLD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Amicus Therapeutics(FOLD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction